Performance highlights
- In this fourth quarter of 2022/2023 (July -
September 2023 ),CS MEDICA delivered net sales of tDKK 73 (9.255) meeting the revised goal of Net Sales Year-to-date of mDKK 1. In the quarter we obtained an order intake of mDKK 2.8 in Q4, which accumulates to mDKK 14,5 year-to-date. - Operating loss for the fourth quarter amounted to tDKK 4.640, compared to tDKK 99 last year.
- Cash and Cash equivalents at the end of the fourth Quarter of 2022/2023, close at tDKK -415 (2.934). To fortify
CS MEDICA's liquidity, the focus remains on short-term sales and the factoring agreement with Svea. Concurrently, we're looking into the possibilities of facilitating a swift bank transfer in collaboration with our Investor, RongShi, while exploring alternative funding solutions to ensure financial stability. -
The long-term funding is attained by the company's Investment Agreement with RongShi, with a cash capital increase (direct issue) at a share price of
DKK 28.13 . The direct issue amounts to mDKK 60 corresponding to 14.76% ofCS MEDICA 's outstanding shares on a non-diluted basis. -
At the end of the period,
CS MEDICA's equity/asset ratio was 40% (89%)
Significant events during the fourth quarter (July -
Sep 18, 2023 ,CS MEDICA announces the initiation of the registration process for its six medical devices inMalaysia . This initiative is undertaken in partnership withRongshi MEDICA Co. Ltd. ("RongShi Medica" or the "Joint Venture").Sep 06, 2023 ,CS MEDICA 's Joint Venture with RongShi Successfully Represented at CPHI & PMEC China 2023.Aug 30, 2023 ,CS MEDICA achieves Milestone with Patent on NasalNight Spray .Jul 18, 2023 ,CS MEDICA releases Q3 2022/2023 report.Jul 14, 2023 ,CS MEDICA finalized the establishment and registration ofCANNORDIC India Pvt. Ltd to Expand Presence inIndia .
Significant events after the period
Oct 31, 2023 ,CS MEDICA received its second-issued patent on its "Nasal Protect Gel," providing protection against pollen, bacteria, viruses, and pollution.Oct 26, 2023 ,CS MEDICA received certificates of registration for the trademark CANNASEN® inAustralia .Oct 12, 2023 , CS MEDICA Announces Indian State's FDA Approval for Two Cosmetic Products.Oct 10, 2023 ,Danske Bank has extended a1,2 million DKK credit line toCS MEDICA , reaffirming its confidence in the company. This funding bolstersCS MEDICA as they awaitChina -backed support, linked to Chinese FDA approval of 3-5 Medical Device products.Oct 09, 2023 ,CS MEDICA , is selected as a finalist in the 2023 European Lifestars Awards. The company has been recognized in the category of "Post-IPO Raise of the Year," organized by LSX, a network for life science executive leaders.
Live streamed conference following the Q4 2022/2023 Report
On Tuesday
Please register, submit questions now or during the live presentation and vote for the best questions at the following link >>
Date and time
Tuesday 5th of December, 2023, from
Sign up for conference
Live conference sign-up link >>
For more information about
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
The company is listed on
https://news.cision.com/cs-medica-a-s/r/cs-medica-a-s--release-of-2022-2023-q4-report--for-the-period-july---september-2023--including-an-in,c3879718
https://mb.cision.com/Main/20740/3879718/2448433.pdf
(c) 2023 Cision. All rights reserved., source